PMID- 29211355
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20181023
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 26
IP  - 7
DP  - 2017 Oct
TI  - Tumor marker alpha-fetoprotein receptor does not discriminate between benign 
      prostatic disease and prostate cancer.
PG  - 1085-1090
LID - 10.17219/acem/65432 [doi]
AB  - BACKGROUND: The alpha-fetoprotein receptor (RECAF) is a proposed novel tumor marker 
      for detecting several different types of tumors, including prostate cancer (PCa). 
      OBJECTIVES: The aim of the study was to evaluate RECAF in discriminating benign 
      prostatic conditions from PCa and to compare it with prostate-specific antigen 
      (PSA). MATERIAL AND METHODS: A total of 64 patients with elevated serum PSA 
      levels and/or abnormal digital rectal examination of the prostate referred to a 
      tertiary center for transrectal ultrasound (TRUS) biopsy of the prostate were 
      prospectively enrolled in the study from January 2009 to April 2010. Serum RECAF, 
      total PSA (tPSA) and free PSA (fPSA) concentrations were measured. The results 
      were correlated with histopathologic findings using the Mann-Whitney U test and 
      Kruskal-Wallis chi2 test. RESULTS: The median RECAF concentration was 5.34 U/L in 
      the benign pathology group of patients and 4.72 U/L in the malignant pathology 
      group. The difference was not statistically significant. RECAF density, tPSA and 
      fPSA concentrations and tPSA density were significantly different between the 
      benign and malignant pathology groups (p = 0.033, p = 0.000, p = 0.002 and p = 
      0.000, respectively). RECAF concentration and RECAF density did not differ 
      significantly in the subgroups of PCa patients stratified according to Gleason 
      score, predominant primary Gleason grade or maximum primary Gleason grade, but in 
      predominant secondary Gleason grade and maximum secondary Gleason grade, 
      significant differences were found (p = 0.007 and p = 0.004, respectively). 
      CONCLUSIONS: The results of the study did not confirm the RECAF tumor marker as 
      an alternative way to discriminate between groups of patients with benign 
      prostatic conditions and PCa, and its concentration and density do not differ 
      among PCa histopathologic groups.
FAU - Smrkolj, Tomaz
AU  - Smrkolj T
AD  - Department of Urology, Ljubljana University Medical Centre, Slovenia.
FAU - Gubina, Borut
AU  - Gubina B
AD  - Department of Urology, Ljubljana University Medical Centre, Slovenia.
FAU - Bizjak, Jure
AU  - Bizjak J
AD  - Department of Urology, Ljubljana University Medical Centre, Slovenia.
FAU - Kumer, Kristina
AU  - Kumer K
AD  - Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical 
      Centre, Slovenia.
FAU - Fabjan, Teja
AU  - Fabjan T
AD  - Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical 
      Centre, Slovenia.
FAU - Osredkar, Josko
AU  - Osredkar J
AD  - Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical 
      Centre, Slovenia.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Peptide)
RN  - 0 (alpha-fetoprotein receptor, human)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Diagnosis, Differential
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Diseases/*diagnosis
MH  - Prostatic Neoplasms/blood/*diagnosis/pathology
MH  - Receptors, Peptide/*analysis
MH  - Statistics, Nonparametric
OTO - NOTNLM
OT  - histopathology
OT  - prostate cancer
OT  - prostate-specific antigen
OT  - tumor marker
OT  - alpha-fetoprotein receptor
EDAT- 2017/12/07 06:00
MHDA- 2018/03/14 06:00
CRDT- 2017/12/07 06:00
PHST- 2017/12/07 06:00 [entrez]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
AID - 10.17219/acem/65432 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2017 Oct;26(7):1085-1090. doi: 10.17219/acem/65432.